Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy

REFERENCES

1. 1.↵
   1. Cornford P,
   2. Bellmunt J,
   3. Bolla M,
   4. et al.

   EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Gillessen S,
   2. Omlin A,
   3. Attard G,
   4. et al.

   Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCC) 2015. Ann Oncol. 2015;26(8):1589-1604. doi: 10.1093/annonc/mdv257

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Gillessen S,
   2. Attard G,
   3. Beer TM,
   4. et al.

   Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCC 2017. Eur Urol. 2018;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002

   OpenUrlCrossRef
4. 4.↵
   1. James ND,
   2. de Bono JS,
   3. Spears MR

   , et al; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338-351. doi: 10.1056/NEJMoa1702900

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Fizazi K,
   2. Tran N,
   3. Fein L,
   4. et al.

   Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-360. doi: 10.1056/NEJMoa1704174

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Ingrosso G,
   2. Trippa F,
   3. Maranzano E,
   4. et al.

   Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35(1):45-49. doi: 10.1007/s00345-016-1860-0

   OpenUrlCrossRef
7. 7.↵
   1. Triggiani L,
   2. Mazzola R,
   3. Magrini SM,
   4. et al.

   Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37(12):2631-2637. doi: 10.1007/s00345-019-02717-7

   OpenUrlCrossRef
8. 8.↵
   1. Patel PH,
   2. Chaw CL,
   3. Tree AC,
   4. Sharabiani M,
   5. van As NJ

   . Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World J Urol. 2019;37(12):2615-2621. doi: 10.1007/s00345-019-02873-w

   OpenUrlCrossRef
9. 9.
   1. Muacevic A,
   2. Kufeld M,
   3. Rist C,
   4. Wowra B,
   5. Stief C,
   6. Staehler M

   . Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013;31(4):455-460. doi: 10.1016/j.urolonc.2011.02.023

   OpenUrlCrossRefPubMed
10. 10.
    1. Habl G,
    2. Straube C,
    3. Schiller K,
    4. et al.

    Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer. 2017;17(1):361. doi: 10.1186/s12885-017-3341-2

    OpenUrlCrossRef
11. 11.↵
    1. Fanetti G,
    2. Marvaso G,
    3. Ciardo D,
    4. et al.

    Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. Med Oncol. 2018;35(5):75. doi: 10.1007/s12032-018-1137-0

    OpenUrlCrossRef
12. 12.↵
    1. Decaestecker K,
    2. De Meerleer G,
    3. Lambert B,
    4. et al.

    Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135. doi: 10.1186/1748-717X-9-135

    OpenUrlCrossRefPubMed
13. 13.
    1. Magee DE,
    2. Singal RK

    . Androgen deprivation therapy: indications, methods of utilization, side effect and their management. Canadian J Urol. 2020;27(27 Suppl 1):11-16.

    OpenUrl
14. 14.↵
    1. Martinez-Fernandez MI,
    2. Perez Gracia JL,
    3. Gil-Bazo I,
    4. Martinez-Monge R

    . Stereotactic body radiotherapy (SBRT) can delays the emergence of castration resistance in patients with oligometastatic prostate cancer. Clin Trans Oncol. 2016;18(7):742-747. doi: 10.1007/s12094-015-1414-8

    OpenUrlCrossRef
15. 15.↵
    1. Evans JD,
    2. Jethwa KL,
    3. Ost P,
    4. et al.

    Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol. 2018;8(1):28-39. doi: 10.1016/j.prro.2017.07.011

    OpenUrlCrossRef